PubMed:28442599 JSONTXT

{"project":"sonoma2","denotations":[{"id":"T61","span":{"begin":1396,"end":1402},"obj":"GENE"},{"id":"T0","span":{"begin":0,"end":10},"obj":"NEGREG"},{"id":"T1","span":{"begin":35,"end":47},"obj":"DISEASE"},{"id":"T2","span":{"begin":60,"end":78},"obj":"GENE"},{"id":"T3","span":{"begin":79,"end":89},"obj":"NEGREG"},{"id":"T4","span":{"begin":93,"end":99},"obj":"GENE"},{"id":"T5","span":{"begin":93,"end":103},"obj":"GENE"},{"id":"T6","span":{"begin":101,"end":114},"obj":"VAR"},{"id":"T7","span":{"begin":118,"end":127},"obj":"GENE"},{"id":"T8","span":{"begin":146,"end":156},"obj":"REG"},{"id":"T9","span":{"begin":206,"end":215},"obj":"REG"},{"id":"T10","span":{"begin":227,"end":232},"obj":"DISEASE"},{"id":"T11","span":{"begin":243,"end":252},"obj":"CPA"},{"id":"T12","span":{"begin":254,"end":262},"obj":"GENE"},{"id":"T13","span":{"begin":284,"end":296},"obj":"REG"},{"id":"T14","span":{"begin":314,"end":319},"obj":"DISEASE"},{"id":"T15","span":{"begin":335,"end":346},"obj":"REG"},{"id":"T16","span":{"begin":355,"end":363},"obj":"GENE"},{"id":"T17","span":{"begin":400,"end":412},"obj":"DISEASE"},{"id":"T18","span":{"begin":405,"end":416},"obj":"DISEASE"},{"id":"T19","span":{"begin":462,"end":470},"obj":"GENE"},{"id":"T20","span":{"begin":555,"end":563},"obj":"GENE"},{"id":"T21","span":{"begin":580,"end":583},"obj":"NEGREG"},{"id":"T22","span":{"begin":594,"end":606},"obj":"DISEASE"},{"id":"T23","span":{"begin":595,"end":607},"obj":"DISEASE"},{"id":"T24","span":{"begin":692,"end":704},"obj":"DISEASE"},{"id":"T25","span":{"begin":693,"end":705},"obj":"DISEASE"},{"id":"T26","span":{"begin":730,"end":741},"obj":"REG"},{"id":"T27","span":{"begin":750,"end":758},"obj":"GENE"},{"id":"T28","span":{"begin":763,"end":783},"obj":"CPA"},{"id":"T29","span":{"begin":787,"end":799},"obj":"DISEASE"},{"id":"T30","span":{"begin":788,"end":800},"obj":"DISEASE"},{"id":"T31","span":{"begin":831,"end":841},"obj":"NEGREG"},{"id":"T32","span":{"begin":842,"end":850},"obj":"GENE"},{"id":"T33","span":{"begin":851,"end":862},"obj":"MPA"},{"id":"T34","span":{"begin":877,"end":891},"obj":"VAR"},{"id":"T35","span":{"begin":895,"end":903},"obj":"GENE"},{"id":"T36","span":{"begin":904,"end":914},"obj":"POSREG"},{"id":"T37","span":{"begin":915,"end":927},"obj":"DISEASE"},{"id":"T38","span":{"begin":916,"end":928},"obj":"DISEASE"},{"id":"T39","span":{"begin":972,"end":978},"obj":"GENE"},{"id":"T40","span":{"begin":973,"end":983},"obj":"GENE"},{"id":"T41","span":{"begin":991,"end":997},"obj":"MPA"},{"id":"T42","span":{"begin":1001,"end":1009},"obj":"GENE"},{"id":"T43","span":{"begin":1045,"end":1057},"obj":"DISEASE"},{"id":"T44","span":{"begin":1049,"end":1061},"obj":"DISEASE"},{"id":"T45","span":{"begin":1086,"end":1094},"obj":"POSREG"},{"id":"T46","span":{"begin":1095,"end":1101},"obj":"GENE"},{"id":"T47","span":{"begin":1099,"end":1109},"obj":"GENE"},{"id":"T48","span":{"begin":1102,"end":1112},"obj":"MPA"},{"id":"T49","span":{"begin":1127,"end":1134},"obj":"DISEASE"},{"id":"T50","span":{"begin":1143,"end":1157},"obj":"VAR"},{"id":"T51","span":{"begin":1161,"end":1169},"obj":"GENE"},{"id":"T52","span":{"begin":1170,"end":1183},"obj":"POSREG"},{"id":"T53","span":{"begin":1213,"end":1222},"obj":"CPA"},{"id":"T54","span":{"begin":1231,"end":1241},"obj":"NEGREG"},{"id":"T55","span":{"begin":1245,"end":1251},"obj":"GENE"},{"id":"T56","span":{"begin":1254,"end":1264},"obj":"GENE"},{"id":"T57","span":{"begin":1308,"end":1320},"obj":"DISEASE"},{"id":"T58","span":{"begin":1320,"end":1332},"obj":"DISEASE"},{"id":"T59","span":{"begin":1363,"end":1374},"obj":"REG"},{"id":"T60","span":{"begin":1383,"end":1391},"obj":"GENE"},{"id":"T62","span":{"begin":1408,"end":1418},"obj":"GENE"},{"id":"T63","span":{"begin":1492,"end":1503},"obj":"DISEASE"},{"id":"T64","span":{"begin":1495,"end":1503},"obj":"GENE"},{"id":"T65","span":{"begin":1534,"end":1551},"obj":"MPA"},{"id":"T66","span":{"begin":1556,"end":1568},"obj":"DISEASE"},{"id":"T67","span":{"begin":1577,"end":1589},"obj":"DISEASE"}],"relations":[{"id":"R0","pred":"ThemeOf","subj":"T1","obj":"T0"},{"id":"R1","pred":"ThemeOf","subj":"T1","obj":"T3"},{"id":"R2","pred":"ThemeOf","subj":"T4","obj":"T3"},{"id":"R3","pred":"CauseOf","subj":"T6","obj":"T8"},{"id":"R4","pred":"CauseOf","subj":"T6","obj":"T9"},{"id":"R5","pred":"ThemeOf","subj":"T7","obj":"T6"},{"id":"R6","pred":"ThemeOf","subj":"T7","obj":"T8"},{"id":"R7","pred":"ThemeOf","subj":"T11","obj":"T8"},{"id":"R8","pred":"ThemeOf","subj":"T11","obj":"T9"},{"id":"R9","pred":"ThemeOf","subj":"T12","obj":"T13"},{"id":"R10","pred":"ThemeOf","subj":"T16","obj":"T15"},{"id":"R11","pred":"ThemeOf","subj":"T17","obj":"T15"},{"id":"R12","pred":"ThemeOf","subj":"T20","obj":"T21"},{"id":"R13","pred":"ThemeOf","subj":"T22","obj":"T21"},{"id":"R14","pred":"ThemeOf","subj":"T24","obj":"T26"},{"id":"R15","pred":"ThemeOf","subj":"T27","obj":"T26"},{"id":"R16","pred":"ThemeOf","subj":"T27","obj":"T33"},{"id":"R17","pred":"ThemeOf","subj":"T28","obj":"T26"},{"id":"R18","pred":"ThemeOf","subj":"T28","obj":"T31"},{"id":"R19","pred":"ThemeOf","subj":"T29","obj":"T26"},{"id":"R20","pred":"ThemeOf","subj":"T29","obj":"T28"},{"id":"R21","pred":"ThemeOf","subj":"T29","obj":"T31"},{"id":"R22","pred":"ThemeOf","subj":"T33","obj":"T31"},{"id":"R23","pred":"ThemeOf","subj":"T32","obj":"T31"},{"id":"R24","pred":"ThemeOf","subj":"T32","obj":"T33"},{"id":"R25","pred":"ThemeOf","subj":"T33","obj":"T26"},{"id":"R26","pred":"ThemeOf","subj":"T33","obj":"T36"},{"id":"R27","pred":"CauseOf","subj":"T34","obj":"T31"},{"id":"R28","pred":"CauseOf","subj":"T34","obj":"T36"},{"id":"R29","pred":"ThemeOf","subj":"T35","obj":"T33"},{"id":"R30","pred":"ThemeOf","subj":"T35","obj":"T34"},{"id":"R31","pred":"ThemeOf","subj":"T35","obj":"T36"},{"id":"R32","pred":"ThemeOf","subj":"T37","obj":"T36"},{"id":"R33","pred":"ThemeOf","subj":"T39","obj":"T41"},{"id":"R34","pred":"ThemeOf","subj":"T42","obj":"T41"},{"id":"R35","pred":"ThemeOf","subj":"T48","obj":"T45"},{"id":"R36","pred":"ThemeOf","subj":"T46","obj":"T48"},{"id":"R37","pred":"CauseOf","subj":"T50","obj":"T52"},{"id":"R38","pred":"CauseOf","subj":"T50","obj":"T54"},{"id":"R39","pred":"ThemeOf","subj":"T51","obj":"T50"},{"id":"R40","pred":"ThemeOf","subj":"T51","obj":"T52"},{"id":"R41","pred":"CauseOf","subj":"T54","obj":"T52"},{"id":"R42","pred":"ThemeOf","subj":"T53","obj":"T52"},{"id":"R43","pred":"ThemeOf","subj":"T55","obj":"T54"},{"id":"R44","pred":"ThemeOf","subj":"T57","obj":"T59"},{"id":"R45","pred":"ThemeOf","subj":"T60","obj":"T59"},{"id":"R46","pred":"ThemeOf","subj":"T61","obj":"T59"},{"id":"R47","pred":"ThemeOf","subj":"T64","obj":"T65"},{"id":"R48","pred":"ThemeOf","subj":"T66","obj":"T65"}],"text":"Overcoming cisplatin resistance in osteosarcoma through the miR-199a-modulated inhibition of HIF-1α.\nDysregulation of microRNAs has been shown to contribute to multiple tumorigenic processes, as well as to correlate with tumor progression and prognosis. MiR-199a has been shown to be dysregulated in multiple tumor types. However, the association between miR-199a and the chemoresistance features of osteosarcoma is not well understood, and the target genes for miR-199a and the regulatory mechanisms are also unknown. In this study, we demonstrated that miR-199a is expressed at low levels in osteosarcoma cells and patient samples. By the selection and establishment of cisplatin resistant osteosarcoma cell line, we observed a correlation between miR-199a and cisplatin resistance in osteosarcoma cells: resistant cells exhibit attenuated miR-199a expressions and exogenous overexpression of miR-199a sensitizes osteosarcoma cells to cisplatin. Moreover, we identified HIF-1α as a direct target of miR-199a. Intriguingly, cisplatin resistant osteosarcoma cells display significantly elevated HIF-1α expression under hypoxia. We report here overexpression of miR-199a re-sensitizes cisplatin resistant cells to cisplatin through inhibition of HIF-1α in vitro and in vivo Finally, by analyzing the clinical osteosarcoma patient samples, we demonstrate a reverse correlation between miR-199a and HIF-1α mRNAs. Our study will provide mechanisms for the microRNAs-mediated anti-cancer therapy and miR-199a may be considered a promising therapeutic agent for osteosarcoma patients who fail to respond to conventional chemotherapy."}